ID   HSJD-DIPG-012
AC   CVCL_VU71
SY   DIPG012; Hospital Sant Joan de Deu-Diffuse Intrinsic Pontine Glioma-012
DR   cancercelllines; CVCL_VU71
DR   Wikidata; Q94303502
RX   Patent=US20200384022;
RX   PubMed=28947132;
RX   PubMed=32229503;
RX   PubMed=34732238;
CC   Sequence variation: Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (Patent=US20200384022; PubMed=32229503; PubMed=34732238).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified (PubMed=32229503; PubMed=34732238).
CC   Derived from site: In situ; Brainstem, pons; UBERON=UBERON_0000988.
ST   Source(s): PubMed=34732238
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 10,11
ST   D16S539: 11,12
ST   D21S11: 28,30
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   TH01: 8
ST   TPOX: 9,11
ST   vWA: 16,18
DI   NCIt; C94764; Diffuse intrinsic pontine glioma
DI   ORDO; Orphanet_497188; Diffuse intrinsic pontine glioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   6Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 19-12-24; Version: 9
//
RX   Patent=US20200384022;
RA   Suva M.L., Bernstein B.E., Regev A., Filbin M.G., Tirosh I., Hovestadt V.;
RT   "Methods and compositions for targeting developmental and oncogenic
RT   programs in H3K27M gliomas.";
RL   Patent number US20200384022, 10-Dec-2020.
//
RX   PubMed=28947132; DOI=10.1016/j.yexcr.2017.09.032;
RA   Meel M.H., Sewing A.C.P., Waranecki P., Metselaar D.S., Wedekind L.E.,
RA   Koster J., van Vuurden D.G., Kaspers G.J.L., Hulleman E.;
RT   "Culture methods of diffuse intrinsic pontine glioma cells determine
RT   response to targeted therapies.";
RL   Exp. Cell Res. 360:397-403(2017).
//
RX   PubMed=32229503; DOI=10.1158/1541-7786.MCR-19-0507;
RA   Wang Z.-H., Xu C., Diplas B.H., Moure C.J., Chen C.-P.J., Chen L.H.,
RA   Du C.-Z., Zhu H.-S., Greer P.K., Zhang L.-W., He Y.-P., Waitkus M.S.,
RA   Yan H.;
RT   "Targeting mutant PPM1D sensitizes diffuse intrinsic pontine glioma
RT   cells to the PARP inhibitor olaparib.";
RL   Mol. Cancer Res. 18:968-980(2020).
//
RX   PubMed=34732238; DOI=10.1186/s40478-021-01270-y; PMCID=PMC8565061;
RA   Xu C., Liu H., Pirozzi C.J., Chen L.H., Greer P.K., Diplas B.H.,
RA   Zhang L.-W., Waitkus M.S., He Y.-P., Yan H.;
RT   "TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are
RT   sensitive to a MDM2 antagonist.";
RL   Acta Neuropathol. Commun. 9:178.1-178.12(2021).
//